Top

Published in:

01-06-2018 | Breast Oncology

The 21-Gene Recurrence Score in Male Breast Cancer

Authors: Gulisa Turashvili, MD, PhD, Monica Gonzalez-Loperena, Edi Brogi, MD, PhD, Maura Dickler, MD, Larry Norton, MD, Monica Morrow, MD, Hannah Y. Wen, MD, PhD

Published in: Annals of Surgical Oncology | Issue 6/2018

Abstract

Background

Given the limited data, systemic treatment of male breast cancer has been extrapolated from female patients. The 21-gene recurrence score (RS) assay estimates the risk of distant recurrence and chemotherapy benefit in early-stage, ER+/HER2− female breast cancer. We assessed the association between RS and type of treatment in male breast cancer.

Methods

We identified male patients with ER+/HER2− breast cancer and available RS results treated at our institution in 2006–2016. We collected data on clinicopathologic features, treatment, and outcome. The Institutional Review Board approved the study.

Results

The study cohort consists of 38 male breast cancer patients with a median age of 70 years. Median tumor size was 1.6 cm, and 81.6% (31) were node-negative. RS was low (≤ 17) in 26 (68.4%) cases, intermediate (18–30) in 9 (23.7%) cases, and high (≥ 31) in 3 (7.9%) cases, comparable to that in female patients at our institution. All patients underwent total mastectomy, and one received radiotherapy. Thirty-four (89.5%) patients received adjuvant endocrine therapy, mostly tamoxifen (81.6%; 31). Five (13.2%) patients with intermediate or high RS were treated with adjuvant chemotherapy. No locoregional recurrence was observed, and one patient developed distant recurrence (median follow-up 34 months).

Conclusions

The RS distribution in male breast cancers was similar to that in females treated at our institution. With limited follow-up, patients with low RS were spared chemotherapy and did not develop recurrence. Our results suggest that the RS may have a clinical utility in male breast cancer patients.

Society AC. Cancer Facts & Figures 2017. Atlanta: American Cancer Society; 2017.

Fentiman IS, Fourquet A, Hortobagyi GN. Male breast cancer. Lancet. 2006;367(9510):595–604. https://doi.org/10.1016/s0140-6736(06)68226-3 CrossRefPubMed

Korde LA, Zujewski JA, Kamin L, Giordano S, Domchek S, Anderson WF, et al. Multidisciplinary meeting on male breast cancer: summary and research recommendations. J Clin Oncol 2010;28(12):2114–22. https://doi.org/10.1200/jco.2009.25.5729 CrossRefPubMedPubMedCentral

Friedman LS, Gayther SA, Kurosaki T, Gordon D, Noble B, Casey G, et al. Mutation analysis of BRCA1 and BRCA2 in a male breast cancer population. Am J Hum Genet. 1997;60(2):313–9.PubMedPubMedCentral

Li X, Yang J, Krishnamurti U, Huo L, Ward KC, O’Regan R, et al. Hormone receptor-positive breast cancer has a worse prognosis in male than in female patients. Clin Breast Cancer. 2017;17(5):356–66. https://doi.org/10.1016/j.clbc.2017.03.005 CrossRefPubMed

Greif JM, Pezzi CM, Klimberg VS, Bailey L, Zuraek M. Gender differences in breast cancer: analysis of 13,000 breast cancers in men from the National Cancer Data Base. Ann Surg Oncol. 2012;19(10):3199–204. https://doi.org/10.1245/s10434-012-2479-z CrossRefPubMed

Piscuoglio S, Ng CK, Murray MP, Guerini-Rocco E, Martelotto LG, Geyer FC, et al.. The genomic landscape of male breast cancers. Clin Cancer Res. 2016;22(16):4045-56. https://doi.org/10.1158/1078-0432.ccr-15-2840 CrossRefPubMedPubMedCentral

Giuliano AE, Connolly JL, Edge SB, Mittendorf EA, Rugo HS, Solin LJ, et al. Breast cancer: major changes in the American Joint Committee on Cancer 8th edition cancer staging manual. CA Cancer J Clin. 2017;67(4):290–303. https://doi.org/10.3322/caac.21393 CrossRefPubMed

Paik S, Shak S, Tang G, Kim C, Baker J, Cronin M, et al. A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med. 2004;351(27):2817-26. https://doi.org/10.1056/nejmoa041588 CrossRefPubMed

10.

Paik S, Tang G, Shak S, Kim C, Baker J, Kim W, et al. Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer. J Clin Oncol. 2006;24(23):3726–34. https://doi.org/10.1200/jco.2005.04.7985 CrossRefPubMed

11.

Lo SS, Mumby PB, Norton J, Rychlik K, Smerage J, Kash J, et al. Prospective multicenter study of the impact of the 21-gene recurrence score assay on medical oncologist and patient adjuvant breast cancer treatment selection. J Clin Oncol. 2010;28(10):1671–6. https://doi.org/10.1200/jco.2008.20.2119 CrossRefPubMed

12.

Ademuyiwa FO, Miller A, O’Connor T, Edge SB, Thorat MA, Sledge GW, et al. The effects of oncotype DX recurrence scores on chemotherapy utilization in a multi-institutional breast cancer cohort. Breast Cancer Res Treat. 2011;126(3):797–802. https://doi.org/10.1007/s10549-010-1329-6 CrossRefPubMed

13.

Geffen DB, Abu-Ghanem S, Sion-Vardy N, Braunstein R, Tokar M, Ariad S, et al. The impact of the 21-gene recurrence score assay on decision making about adjuvant chemotherapy in early-stage estrogen-receptor-positive breast cancer in an oncology practice with a unified treatment policy. Ann Oncol. 2011;22(11):2381–6. https://doi.org/10.1093/annonc/mdq769 CrossRefPubMed

14.

Partin JF, Mamounas EP. Impact of the 21-gene recurrence score assay compared with standard clinicopathologic guidelines in adjuvant therapy selection for node-negative, estrogen receptor-positive breast cancer. Ann Surg Oncol. 2011;18(12):3399–406. https://doi.org/10.1245/s10434-011-1698-z CrossRefPubMed

15.

Albanell J, Gonzalez A, Ruiz-Borrego M, Alba E, Garcia-Saenz JA, Corominas JM, et al. Prospective transGEICAM study of the impact of the 21-gene Recurrence Score assay and traditional clinicopathological factors on adjuvant clinical decision making in women with estrogen receptor-positive (ER+) node-negative breast cancer. Ann Oncol. 2012;23(3):625–31. https://doi.org/10.1093/annonc/mdr278 CrossRefPubMed

16.

Joh JE, Esposito NN, Kiluk JV, Laronga C, Lee MC, Loftus L, et al. The effect of Oncotype DX recurrence score on treatment recommendations for patients with estrogen receptor-positive early stage breast cancer and correlation with estimation of recurrence risk by breast cancer specialists. Oncology 2011;16 (11):1520–6. https://doi.org/10.1634/theoncologist.2011-0045 CrossRef

17.

Eiermann W, Rezai M, Kummel S, Kuhn T, Warm M, Friedrichs K, et al. The 21-gene recurrence score assay impacts adjuvant therapy recommendations for ER-positive, node-negative and node-positive early breast cancer resulting in a risk-adapted change in chemotherapy use. Ann Oncol. 2013;24(3):618–24. https://doi.org/10.1093/annonc/mds512 CrossRefPubMed

18.

Carlson JJ, Roth JA. The impact of the Oncotype Dx breast cancer assay in clinical practice: a systematic review and meta-analysis. Breast Cancer Res Treat 2013;141(1):13–22. https://doi.org/10.1007/s10549-013-2666-z CrossRefPubMedPubMedCentral

19.

Dinan MA, Mi X, Reed SD, Lyman GH, Curtis LH. Association between use of the 21-gene recurrence score assay and receipt of chemotherapy among medicare beneficiaries with early-stage breast cancer, 2005-2009. JAMA Oncol. 2015;1(8):1098–109. https://doi.org/10.1001/jamaoncol.2015.2722 CrossRefPubMed

20.

Levine MN, Julian JA, Bedard PL, Eisen A, Trudeau ME, Higgins B, et al. Prospective evaluation of the 21-gene recurrence score assay for breast cancer decision-making in Ontario. J Clin Oncol. 2015 https://doi.org/10.1200/jco.2015.62.8503

21.

Sparano JA, Gray RJ, Makower DF, Pritchard KI, Albain KS, Hayes DF, et al. Prospective validation of a 21-gene expression assay in breast cancer. N Engl J Med. 2015 https://doi.org/10.1056/nejmoa1510764 PubMedPubMedCentral

22.

Petkov V, Miller DP, Howlader N, Gliner N, Howe W, Schussler NC, et al. Breast cancer specific mortality in patients with early-stage hormone receptor-positive invasive breast cancer and oncotype DX recurrence score results in the SEER database. J Clin Oncol. 2016;34(7 suppl):176.

23.

Vermeulen MA, Slaets L, Cardoso F, Giordano SH, Tryfonidis K, van Diest PJ, et al. Pathological characterisation of male breast cancer: Results of the EORTC 10085/TBCRC/BIG/NABCG International Male Breast Cancer Program. Eur J Cancer. 2017;82:219-27. https://doi.org/10.1016/j.ejca.2017.01.034 CrossRefPubMed

24.

Callari M, Cappelletti V, De Cecco L, Musella V, Miodini P, Veneroni S, et al. Gene expression analysis reveals a different transcriptomic landscape in female and male breast cancer. Breast Cancer Res Treat. 2011;127(3):601–10. https://doi.org/10.1007/s10549-010-1015-8 CrossRefPubMed

25.

Johansson I, Nilsson C, Berglund P, Lauss M, Ringner M, Olsson H, et al. Gene expression profiling of primary male breast cancers reveals two unique subgroups and identifies N-acetyltransferase-1 (NAT1) as a novel prognostic biomarker. Breast Cancer Res. 2012;14(1):R31. https://doi.org/10.1186/bcr3116 CrossRefPubMedPubMedCentral

26.

Eggemann H, Ignatov A, Smith BJ, Altmann U, von Minckwitz G, Rohl FW, et al. Adjuvant therapy with tamoxifen compared to aromatase inhibitors for 257 male breast cancer patients. Breast Cancer Res Treat. 2013;137(2):465–70. https://doi.org/10.1007/s10549-012-2355-3 CrossRefPubMed

27.

Giordano SH, Perkins GH, Broglio K, Garcia SG, Middleton LP, Buzdar AU, et al. Adjuvant systemic therapy for male breast carcinoma. Cancer. 2005;104(11):2359–64. https://doi.org/10.1002/cncr.21526 CrossRefPubMed

28.

Scott-Conner CE, Jochimsen PR, Menck HR, Winchester DJ. An analysis of male and female breast cancer treatment and survival among demographically identical pairs of patients. Surgery. 1999;126(4):775–80; discussion 780–1CrossRefPubMed

29.

Peethambaram PP, Hoskin TL, Day CN, Goetz MP, Habermann EB, Boughey JC. Use of 21-gene recurrence score assay to individualize adjuvant chemotherapy recommendations in ER+/HER2− node positive breast cancer-A National Cancer Database study. NPJ Breast Cancer. (2017) 3:41. https://doi.org/10.1038/s41523-017-0044-4 CrossRefPubMedPubMedCentral

30.

Mamounas EP, Liu Q, Paik S, Baehner FL, Tang G, Jeong JH, et al. 2;1-Gene recurrence score and locoregional recurrence in node-positive/ER-positive breast cancer treated with chemo-endocrine therapy. J Natl Cancer Inst. 2017. https://doi.org/10.1093/jnci/djw259 PubMedPubMedCentral

31.

Brufsky AM. Predictive and prognostic value of the 21-gene recurrence score in hormone receptor-positive, node-positive breast cancer. Am J Clin Oncol. 2014;37(4):404–10. https://doi.org/10.1097/coc.0000000000000086 CrossRefPubMedPubMedCentral

32.

Albain KS, Barlow WE, Shak S, Hortobagyi GN, Livingston RB, Yeh IT, et al. Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal women with node-positive, oestrogen-receptor-positive breast cancer on chemotherapy: a retrospective analysis of a randomised trial. Lancet Oncol. 2010;11(1):55–65. https://doi.org/10.1016/s1470-2045(09)70314-6 CrossRefPubMed

33.

Grenader T, Yerushalmi R, Tokar M, Fried G, Kaufman B, Peretz T, et al. The 21-gene recurrence score assay (Oncotype DX) in estrogen receptor-positive male breast cancer: experience in an Israeli cohort. Oncology. 2014;87(1):1-6. https://doi.org/10.1159/000360793 CrossRefPubMed

34.

Turashvili G, Chou JF, Brogi E, Morrow M, Dickler M, Norton L, etal. 21-Gene recurrence score and locoregional recurrence in lymph node-negative, estrogen receptor-positive breast cancer. Breast Cancer Res Treat. 2017;166(1):69–76. https://doi.org/10.1007/s10549-017-4381-7 CrossRefPubMedPubMedCentral

35.

Leone JP, Zwenger AO, Iturbe J, Leone J, Leone BA, Vallejo CT, et al. Prognostic factors in male breast cancer: a population-based study. Breast Cancer Res Treat. 2016;156(3):539–48. https://doi.org/10.1007/s10549-016-3768-1 CrossRefPubMed

36.

Fisher B, Jeong JH, Anderson S, Bryant J, Fisher ER, Wolmark N. Twenty-five-year follow-up of a randomized trial comparing radical mastectomy, total mastectomy, and total mastectomy followed by irradiation. N Engl J Med. 2002;347(8):567–75. https://doi.org/10.1056/nejmoa020128 CrossRefPubMed

37.

Chodick G, Struewing JP, Ron E, Rutter JL, Iscovich J. Similar prevalence of founder BRCA1 and BRCA2 mutations among Ashkenazi and non-Ashkenazi men with breast cancer: evidence from 261 cases in Israel, 1976-1999. Eur J Med Genet. 2008;51(2):141–7. https://doi.org/10.1016/j.ejmg.2007.11.001 CrossRefPubMed

38.

Deb S, Jene N, Kconfab I, Fox SB. Genotypic and phenotypic analysis of familial male breast cancer shows under representation of the HER2 and basal subtypes in BRCA-associated carcinomas. BMC Cancer. 2012;12:510. https://doi.org/10.1186/1471-2407-12-510 CrossRefPubMedPubMedCentral

39.

Lewin R, Sulkes A, Shochat T, Tsoref D, Rizel S, Liebermann N, et al. Oncotype-DX recurrence score distribution in breast cancer patients with BRCA1/2 mutations. Breast Cancer Res Treat. 2016;157(3):511–6. https://doi.org/10.1007/s10549-016-3836-6 CrossRefPubMed

40.

Halpern N, Sonnenblick A, Uziely B, Divinsky L, Goldberg Y, Hamburger T, et al. Oncotype Dx recurrence score among BRCA1/2 germline mutation carriers with hormone receptors positive breast cancer. Int J Cancer. 2017;140(9):2145–9. https://doi.org/10.1002/ijc.30616 CrossRefPubMed

41.

Shah PD, Patil S, Dickler MN, Offit K, Hudis CA, Robson ME. Twenty-one-gene recurrence score assay in BRCA-associated versus sporadic breast cancers: differences based on germline mutation status. Cancer. 2016;122(8):1178–84. https://doi.org/10.1002/cncr.29903 CrossRefPubMed

Title: The 21-Gene Recurrence Score in Male Breast Cancer
Authors: Gulisa Turashvili, MD, PhD
Monica Gonzalez-Loperena
Edi Brogi, MD, PhD
Maura Dickler, MD
Larry Norton, MD
Monica Morrow, MD
Hannah Y. Wen, MD, PhD
Publication date: 01-06-2018
Publisher: Springer International Publishing
Published in: Annals of Surgical Oncology / Issue 6/2018
Print ISSN: 1068-9265
Electronic ISSN: 1534-4681
DOI: https://doi.org/10.1245/s10434-018-6411-z

Keynote webinar | Spotlight on medication adherence

Springer Medicine

The 21-Gene Recurrence Score in Male Breast Cancer

Abstract

Background

Methods

Results

Conclusions

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Background

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 6/2018

Centralization of Esophagectomy in the United States: Might It Benefit Underserved Populations?

Adequate Local Control in High-Risk Soft Tissue Sarcoma of the Extremity Treated with Surgery Alone at a Reference Centre: Should Radiotherapy Still be a Standard?

Advancing the Quality of Care for Newly Diagnosed Prostate Cancer Patients: Novel Uses of Patient-Reported Outcomes

2018 Presidential Address—Society of Surgical Oncology: The Fundamental Difference Between Cancer Treatment and Patient Care

Treatment Strategies in Octogenarians with Early-Stage, High-Risk Breast Cancer

A National-Level Validation of the New American Joint Committee on Cancer 8th Edition Subclassification of Stage IIA and B Anal Squamous Cell Cancer